GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Mapk1 | decreases expression | EXP | | 6480464 | CTD | Fluoxetine results in decreased expression of MAPK1 mRNA | PMID:21753012 | Mapk1 | increases expression | EXP | | 6480464 | CTD | Fluoxetine results in increased expression of MAPK1 protein | PMID:15138445 | Mapk1 | multiple interactions | EXP | | 6480464 | CTD | [Fluoxetine co-treated with Methylphenidate] results in increased expression of MAPK1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MAPK1 protein; Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK1 protein; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK1 protein] | PMID:15456934 PMID:18573488 PMID:21753012 | Mapk1 | decreases phosphorylation | ISO | MAPK1 (Homo sapiens) | 6480464 | CTD | Fluoxetine results in decreased phosphorylation of MAPK1 protein | PMID:18836303 | Mapk1 | increases phosphorylation | ISO | Mapk1 (Mus musculus) | 6480464 | CTD | Fluoxetine results in increased phosphorylation of MAPK1 protein | PMID:16413968 PMID:18758753 PMID:24125781 | Mapk1 | multiple interactions | ISO | Mapk1 (Mus musculus) | 6480464 | CTD | 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein; [Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein; ADARB1 protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]]; bisindolylmaleimide I inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]; HTR2B protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein] | PMID:18758753 PMID:19662385 PMID:21320410 | |
Go Back to source page | Continue to Ontology report |